How this fund's holdings score on the six lenses, weighted by holding weight — plus what the manager is actively buying and selling. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
What's a “leader”? A holding that ranks in the top two deciles (D9 / D10) of its size cohort on BOTH active conviction lenses — Technical and Flow. Leadership-breadth is the share of the fund's weight sitting in those leaders.
Risk & return
Compound returns and the risk taken to earn them, from the fund's own NAV history.
| Sector | 29 Mar | 06 Apr | 04 May | 26 Jun | 06 Jul | 11 Jul | Δ |
|---|---|---|---|---|---|---|---|
| Pharma | 55.6 | 55.6 | 59.9 | 49.8 | 49.8 | 49.8 | -5.8 |
| Healthcare | 29.5 | 29.5 | 25.1 | 35.3 | 35.3 | 35.3 | +5.8 |
| Chemicals | 7.1 | 7.1 | 7.2 | 6.7 | 6.7 | 6.7 | -0.4 |
| Unclassified | 4.1 | 4.1 | 4.1 | 4.0 | 4.0 | 4.0 | -0.1 |
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
—
—
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Pharma | 9.56% | 10 | 8 | 6 | 4 | 2 | 1/2 | +13.9% |
| JBCHEPHARM | Pharma | 6.80% | 9 | 7 | 2 | 5 | 1 | 1/2 | +18.6% |
| APOLLOHOSP | Healthcare | 4.83% | 10 | 5 | 7 | 2 | 2 | 0/2 | +14.5% |
| LAURUSLABS | Pharma | 4.43% | 8 | 9 | 4 | 4 | 1 | 0/2 | +34.0% |
| FORTIS | Healthcare | 3.92% | 8 | 8 | 5 | 2 | 3 | 0/2 | +8.9% |
| KIMS | Healthcare | 3.44% | 7 | 3 | 7 | 4 | 1 | 0/2 | +19.2% |
| DIVISLAB | Pharma | 3.29% | 10 | 8 | 1 | 6 | 1 | 1/2 | +8.1% |
| SAILIFE | Healthcare | 3.17% | 8 | 9 | 6 | 5 | 2 | 0/2 | +20.3% |
| MAXHEALTH | Healthcare | 2.83% | 7 | 9 | 5 | 4 | 3 | 0/2 | +12.2% |
| AUROPHARMA | Pharma | 2.62% | 9 | 3 | 10 | 6 | 6 | 0/2 | +14.4% |
| NEULANDLAB | Healthcare | 2.53% | 10 | 10 | 5 | 10 | 2 | 1/2 | +27.4% |
| ACUTAAS | Chemicals | 2.46% | 8 | 10 | 2 | 5 | 1 | 0/2 | +43.1% |
| LALPATHLAB | Healthcare | 2.11% | 10 | 8 | 7 | 1 | 3 | 0/2 | +16.6% |
| GLAND | Pharma | 1.99% | 9 | 8 | 6 | 6 | 4 | 0/2 | +38.5% |
| NH | Healthcare | 1.88% | 9 | 8 | 8 | 2 | 3 | 0/2 | +10.3% |
| ASTERDM | Healthcare | 1.80% | 10 | 4 | 8 | 3 | 1 | 1/2 | +15.1% |
| AJANTPHARM | Pharma | 1.68% | 8 | 10 | 1 | 4 | 3 | 0/2 | +14.6% |
| ZYDUSLIFE | Pharma | 1.61% | 10 | 10 | 10 | 10 | 6 | 1/2 | +23.3% |
| RAINBOW | Healthcare | 1.59% | 10 | 7 | 2 | 5 | 4 | 1/2 | +15.3% |
| GLENMARK | Pharma | 1.35% | 6 | 9 | 10 | 4 | 3 | 0/2 | +1.5% |
| VIJAYA | Pharma | 1.31% | 8 | 10 | 4 | 2 | 1 | 0/2 | +37.0% |
| GRANULES | Healthcare | 1.30% | 10 | 9 | 5 | 6 | 5 | 1/2 | +36.3% |
| ONESOURCE | Healthcare | 1.26% | 3 | 1 | 5 | 7 | 8 | 0/2 | +9.7% |
| NAVINFLUOR | Chemicals | 1.17% | 9 | 10 | 3 | 9 | 1 | 0/2 | +21.1% |
| PFIZER | Healthcare | 1.10% | 3 | 7 | 1 | 2 | 7 | 0/2 | -9.0% |
| ANTHEM | Pharma | 0.94% | 7 | 10 | 3 | 5 | 2 | 0/2 | -2.3% |
| IPCALAB | Pharma | 0.92% | 10 | 6 | 1 | 8 | 4 | 1/2 | +18.3% |
| POLYMED | Healthcare | 0.90% | 5 | 6 | 6 | 6 | 5 | 0/2 | +9.3% |
| CIPLA | Pharma | 0.69% | 6 | 3 | 5 | 3 | 6 | 0/2 | +13.9% |
| ABBOTINDIA | Pharma | 0.58% | 4 | 9 | — | 8 | 7 | 0/2 | +0.6% |
| COHANCE | Healthcare | 0.27% | 4 | 5 | 4 | 10 | 4 | 0/2 | +13.2% |
| MANKIND | Pharma | 0.00% | 10 | 8 | 9 | 5 | 2 | 0/2 | +18.5% |
Performance · 2.4y
Over the last 2.4 years ₹100 in the fund grew to ₹160 (+60%), vs ₹114 for Nifty 500 (+14%) and ₹109 for Nifty 50 (+9%). Its relative-strength line ended at 147 vs Nifty 50 and 141 vs Nifty 500 — above 100, sustained outperformance.